Anne Armstrong

12.8k total citations · 3 hit papers
118 papers, 5.2k citations indexed

About

Anne Armstrong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Anne Armstrong has authored 118 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 31 papers in Genetics. Recurrent topics in Anne Armstrong's work include Advanced Breast Cancer Therapies (40 papers), PARP inhibition in cancer therapy (23 papers) and BRCA gene mutations in cancer (20 papers). Anne Armstrong is often cited by papers focused on Advanced Breast Cancer Therapies (40 papers), PARP inhibition in cancer therapy (23 papers) and BRCA gene mutations in cancer (20 papers). Anne Armstrong collaborates with scholars based in United Kingdom, United States and France. Anne Armstrong's co-authors include Seock‐Ah Im, Mark E. Robson, Nadine Tung, Binghe Xu, Elżbieta Senkus, Pierfranco Conté, Norikazu Masuda, Susan M. Domchek, Suzette Delaloge and Carsten Goessl and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anne Armstrong

110 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. Annals of Oncology profile →
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Anne Armstrong

Since Specialization

Citations

This map shows the geographic impact of Anne Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Armstrong more than expected).

Fields of papers citing papers by Anne Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Armstrong. The network helps show where Anne Armstrong may publish in the future.

Co-authorship network of co-authors of Anne Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Armstrong. A scholar is included among the top collaborators of Anne Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Armstrong. Anne Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Distant recurrence and margin involvement in invasive breast cancer 2026 ·British Journal of Cancer ·Sarah Michael, John Broggio, (unknown), (unknown), Anne Armstrong, (unknown), (unknown), (unknown), Jacqui Gath, Glen P. Martin, (unknown)	0
2	H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). 2024 ·Journal of Clinical Oncology ·Erika Hamilton, Timothy Pluard, Judy S. Wang, Aki Morikawa, Stephen Johnston, Elizabeth Claire Dees, Christos Vaklavas, Anne Armstrong, Pamela N. Münster, Nisha Unni, (unknown), Fadi Kayali, Tingting Song, (unknown), (unknown), Dejan Juric	4
3	OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer 2023 ·European Journal of Cancer ·Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, (unknown), Anitra Fielding, A. Allen, Pierfranco Conté	54
4	Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial 2023 ·International Journal of Cancer ·Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conté, Seock‐Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark E. Robson, Nadine Tung	16
5	Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial 2023 ·Clinical Cancer Research ·Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, (unknown), Frederik Marmé, Carolina P. Schröder, Jens Huober, François P. Duhoux, Peter Vuylsteke, Agnes Jager, Étienne Brain, (unknown), Zsuzsanna Pápai, C. Willemien Menke‐van der Houven van Oordt, (unknown), (unknown), Chrystelle Brignone, Frédéric Triebel	12
6	CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis 2023 ·Breast Cancer Research and Treatment ·Roya Behrouzi, Anne Armstrong, Sacha J. Howell	3
7	186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC) 2023 ·ESMO Open ·Tanja Fehm, (unknown), (unknown), Fabrice André, Ian E. Krop, Y.H. Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruíz Borrego, Rinat Yerushalmi, François P. Duhoux, Toshimi Takano, Wenjun Lü, (unknown), Anton Egorov, S-B. Kim	4
8	1722P Longitudinal analysis of biochemical and haematological features of cancer patients with COVID-19 2020 ·Annals of Oncology ·Ann Tivey, Rohan Shotton, Rebecca Lee, (unknown), Kathryn Banfill, (unknown), Fábio Gomes, Jamie Weaver, Anne Armstrong, Tim Cooksley	1
9	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer breakdown → 2019 ·Annals of Oncology ·Mark E. Robson, Nadine Tung, Pierfranco Conté, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong, Weiwen Wu, Carsten Goessl, Sarah Runswick, Susan M. Domchek	497
10	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial 2019 ·European Journal of Cancer ·Mark E. Robson, Kathryn J. Ruddy, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Wei Li, Nadine Tung, Anne Armstrong, Suzette Delaloge, Wendy Bannister, Carsten Goessl, Arnold Degboe, Robert Hettle, Pierfranco Conté	57
11	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im	67
12	Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. 2017 ·Journal of Clinical Oncology ·Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, Minetta C. Liu, Hiroji Iwata, Larisa Ryvo, Pauline Wimberger, Deborah Card, Yu Ding, Vassiliki Karantza, Peter Schmid	55
13	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation breakdown → 2017 ·New England Journal of Medicine ·Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, Pierfranco Conté	2156
14	Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK 2017 ·European Journal of Surgical Oncology ·J. Loncaster, Anne Armstrong, Sacha J. Howell, G. Wilson, Roy D. Welch, (unknown), William J. Valentine, Nigel Bundred	50
15	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer 2010 ·Breast Cancer Research and Treatment ·Ruth Board, Andrew Wardley, J. Michael Dixon, Anne Armstrong, Sacha J. Howell, Lorna Renshaw, Emma Donald, Alastair Greystoke, Malcolm Ranson, Andrew Hughes, Caroline Dive	165
16	Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma 2005 ·BioDrugs ·Anne Armstrong, Eleanor J. Cheadle, Robert E. Hawkins	2
17	Use of adenoviruses encoding CD40L or IL‐2 against B cell lymphoma 2004 ·International Journal of Cancer ·(unknown), Tapan Bhattacharyya, Anne Armstrong, Cheng Qian, Robert E. Hawkins, Peter L. Stern, Said Dermime	16
18	The Quiet Revolution: Reference Services in Public Libraries 2002 ·Australasian public libraries and information services ·Anne Armstrong	1
19	Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope 2002 ·The Journal of Immunology ·Anne Armstrong, Said Dermime, (unknown), Tapan Bhattacharyya, (unknown), (unknown), Peter L. Stern, Robert E. Hawkins	42
20	Cancer vaccines and immunotherapy 2002 ·British Medical Bulletin ·Said Dermime, Anne Armstrong, Robert E. Hawkins, Peter L. Stern	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact